Gothenburg, Sweden, May 21st, 2012 – Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies, today announces the launch of a human iPS derived hepatocyte product, hiPS-HEPTM.
The hiPS-HEPTM demonstrate high reproducibility, homogeneity and a long life span of stable CYP activity, making them the ideal platform for various in vitro applications including drug discovery, toxicity testing and vaccine development. The hiPS-HEP™ are human hepatocyte-like cells derived from human induced Pluripotent Stem (iPS) cells under strict quality controlled and ethically approved procedures. 上海普迈生物提供在各个领域的国际知名品牌产品，如：Jena Bioscience、Omicron、Eurogentec、Leinco technologies、Smartox、Osenses等试剂与耗材品牌，欢迎来电咨询